Drugs / SAR425899
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03376802 | Apr → Dec 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03414736 | Jan → Oct 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03350191 | Dec 2017 → Jun 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02411825 | Mar 2015 → Jan 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03437720 | May 2019 → Aug 2021 | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Sanofi | Withdrawn | No outcome recorded |
| Phase 2 | NCT02973321 | Dec 2016 → Dec 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR425899 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02973321 ↗ |
| Action | Activate | “active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCR)” PMID 30091218 ↗ Sep 20181“Glucagon receptor agonist” CHEMBL3545269 ↗ |
| Modality | Peptide | “SAR425899, a novel polypeptide, active as an agonist” PMID 30091218 ↗ Sep 2018 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT02411825 ↗ |
| Target | GCGR | “Glucagon receptor agonist” CHEMBL3545269 ↗ |